Acute Myelogenous Leukemia Clinical Trial
Official title:
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
Verified date | March 2012 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
Primary objectives:
- To determine the maximum tolerated dose (MTD) of SAR103168 and to characterize the dose
limiting toxicities (DLTs) in the proposed dose regimen
- To evaluate the pharmacokinetic (PK) profile of SAR103168
Secondary objectives:
- To characterize the global safety profile of SAR103168
- To evaluate preliminary anti-leukemia activity
- To investigate the potential induction effect on CYP3A4 and persistence of this effect
by using oral midazolam as a probe substrate in patients enrolled into the expanded
cohort at the MTD
- To determine the metabolic pathways of SAR103168 and identify the chemical structures
of metabolites
- To determine the potential impact of SAR103168 on the QTc interval in patients enrolled
at the MTD
Status | Completed |
Enrollment | 30 |
Est. completion date | February 2012 |
Est. primary completion date | January 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients with refractory/relapsed acute leukemias or high-risk myelodysplastic syndromes with no curative option available including any of the following: - Patients with de novo or secondary acute myelogenous leukemia (AML) (except acute promyelocytic leukemia), meeting one of the following conditions: - Refractory or relapsed AML; In case of first relapse the CR duration should be less than 12 months. If the relapse failed at least one prior salvage attempt, the CR duration may be more than 12 months. - Into the expanded cohort at the MTD, previously untreated AML patients over age 60 with poor- risk cytogenetics who are not eligible for or do not accept induction chemotherapy may also be included. - Patients with refractory/relapsed acute lymphoblastic leukemia (ALL) - Patients with high-risk myelodysplastic syndrome (MDS) as defined by the International Prognostic Scoring System - Patients with chronic myeloid leukemia in blast phase (CML-BP) Exclusion Criteria: - performance status > 2 - Active uncontrolled central nervous system leukemia - Cytotoxic therapy within 2 weeks prior to the first dose of SAR103168. For the non cytotoxic agents/investigational drugs this washout period should be at least 2 weeks or at least 5 half-lives whichever is longer. Hydroxyurea must be stopped at least 24 hours prior to the first dose of SAR103168 - Lack of recovery from toxicities from prior therapies to grade < 1 - White blood cells > 30 x 10^9/L prior to the first dose of SAR103168 - Prior allogeneic stem cell transplantation or donor lymphocytes infusion within 3 months preceding the first dose of SAR103168 - Any of the following within 6 months prior to the first dose of SAR103168: - Myocardial infarction, congestive heart failure, documented angina pectoris, arrhythmia requiring medication (in particular atrial fibrillation or flutter), severe conduction disorder (second or third atrio-ventricular block, pacemaker), coronary/peripheral artery bypass graft surgery - Arterial or venous thromboembolism, deep venous thrombosis - Left ventricular ejection fraction < 50% by echocardiography or multiple gated acquisition scan - Cardiac ischemia on 12-lead ECG - Baseline QTc-interval > 500 msec - Hypertension uncontrolled with appropriate therapy - Active infection (viral, bacterial or fungal) uncontrolled with appropriate therapy - Major surgery within 6 weeks prior to the first dose of SAR103168 - Poor organ function defined by one of the following: - Total bilirubin > 1.5 x upper limit of normal (ULN) unless related to leukemia (i.e. hemolysis) or Gilbert's syndrome - Aspartate aminotransferase (AST), alanine aminotransferase (ALT) > 2.5 x ULN - Serum creatinine > 1.5 x ULN or calculated creatinine clearance < 50 mL/min - Patients under treatment with potent inhibitors of CYP3A4 unless these treatments may be stopped at least 3 days prior to the first dose of SAR103168 - Patients under treatment with CYP3A4 or CYP2C9 inducers, unless these treatments may be stopped at least 3 days prior to the first dose of SAR103168 - Pregnant or breast-feeding women or refusal to use adequate contraceptive method, when applicable. |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Sanofi-Aventis Investigational Site Number 840003 | Atlanta | Georgia |
United States | Sanofi-Aventis Investigational Site Number 840001 | Houston | Texas |
United States | Sanofi-Aventis Investigational Site Number 840002 | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Sanofi |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of DLTs during the initial 4-week period of treatment | 4 weeks | Yes | |
Primary | Pharmacokinetic parameters of SAR103168 | First course: Days 1, 2, 5, 6, and 8; Second and subsequent courses: Day 5 only | No | |
Secondary | Global safety profile of SAR103168 based on treatment emergent adverse events (TEAEs), serious adverse events (SAEs), deaths, laboratory abnormalities | Treatment period up to 1 year | Yes | |
Secondary | Preliminary evidence of anti-leukemia activity | Treatment period up to 1 year | No | |
Secondary | Pharmacokinetic parameters of midazolam in the absence and the presence of SAR103168. | During second (Day-1 and Day 5) and forth course (Day 5) | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01200355 -
Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
|
Phase 4 | |
Active, not recruiting |
NCT03755414 -
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
|
Phase 1 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02543879 -
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT01681537 -
Lenalidomide Plus Chemotherapy for AML
|
Phase 1 | |
Completed |
NCT01385423 -
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)
|
Phase 1 | |
Terminated |
NCT01193400 -
Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years
|
Phase 2 | |
Completed |
NCT00975975 -
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
|
Phase 2 | |
Completed |
NCT00995332 -
Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine
|
Phase 1/Phase 2 | |
Completed |
NCT00726934 -
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
|
N/A | |
Completed |
NCT00378534 -
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
|
Phase 2 | |
Completed |
NCT01031498 -
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
|
Phase 2 | |
Completed |
NCT00789256 -
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
|
N/A | |
Completed |
NCT00098033 -
Investigation of Clofarabine in Acute Leukemias
|
Phase 2 | |
Completed |
NCT01020539 -
Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia
|
Phase 1 | |
Not yet recruiting |
NCT04709458 -
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
|
Phase 1 | |
Recruiting |
NCT04024241 -
Medium Dose of Cytarabine and Mitoxantrone
|
||
Terminated |
NCT02203773 -
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
|
Phase 1 | |
Terminated |
NCT04023071 -
FT516 in Subjects With Advanced Hematologic Malignancies
|
Phase 1 |